Immunophotonics Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President have announced a partnership that will combine use of Immunophotonics’ lead asset, IP-001 and AngioDynamics’ ablation devices to explore the power of ablation in combination with immunotherapy for the treatment of solid tumor cancers. This collaborative effort extends to a partnership with the Cancer...
Immunophotonics, Inc. is grateful to NCI (National Cancer Institute) SBIR Investor Initiatives Team for providing us the opportunity to showcase our technology at the Global Life Science Partnering & Investor Conference presented by BIOCOM California taking place February 27 – 29, 2024 in La Jolla, California. Immunophotonics is thrilled to take part in this exclusive...
Congratulations to Professor Wei Chen and his lab at the University of Oklahoma, along with contributors Lu Alleruzzo, Samuel S.K. Lam, and Tomas Hode of Immunophotonics, for their publication titled “N-dihydrogalactochitosan serves as an effective mucosal adjuvant for intranasal vaccine in combination with recombinant viral proteins against respiratory infection” in Acta Biomaterialia, an international journal,...
St. Louis cancer drug startup Immunophotonics Inc. will pursue expansion of its lead drug candidate through a partnership with the innovation arm of pharmaceutical giant Johnson & Johnson. (St. Louis INNO/Business Journal article)
Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. will be attending the SIO Annual Scientific Meeting January 26 – 29, in Long Beach, CA. Tomas will be connecting with interventional oncology professionals from around the world on the latest developments in improving cancer care alongside medical, surgical and radiation oncology.
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) are looking forward to attending Spectrum Conference, January 11 – 14, 2024 in Miami, Florida. Leading experts in the field of interventional oncology will be presenting at this prestigious event on the latest advancements in the fight against cancer.
Our networking is well underway with investors and potential strategic partners for the JPM 2024. Attending the annual summit Lu Alleruzzo at JPM Healthcare Conference, Theresa Visarius at JPM Biotech Showcase, and Tomas Hode at RESI, in San Francisco January 8 -12, 2024.
Immunophotonics Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President have announced a research collaboration with Johnson & Johnson Enterprise Innovation Inc. (JJEI) to explore the use of radiation in conjunction with Immunophotonics’ lead drug candidate, IP-001, as a novel immunotherapy approach for the treatment of solid tumor cancers. This collaboration agreement represents a...
Immunophotonics co-founders Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President attending the AngioDynamics International Life Symposium taking place October 26 -28 in Monte Carlo, Monaco. They will be connecting with industry partners and clinical experts from around the world and discussing the latest breakthrough technologies.
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be attending ESMO Conference, October 20 – 24 in Madrid, Spain. They are excited to interact with key leaders, clinicians, researchers, and patient advocates from all over world to learn and brainstorm about the latest in oncology research and treatments.
